Predictive factors of response to anthracylines neoadjuvant chemotherapy in breast cancer

被引:1
作者
Bensouda, Y. [1 ]
Ismaili, N. [1 ]
Ahbeddou, N. [1 ]
El Hassani, K. [1 ]
Chenna, M. [2 ]
Sbitti, Y. [1 ]
Boutayeb, S. [1 ]
Errihani, H. [1 ]
机构
[1] Inst Natl Oncol, Med Oncol Serv, Rabat, Morocco
[2] Ctr Hosp Ibn Sina, Serv Chirurg Viscerale A, Rabat, Morocco
来源
GYNECOLOGIE OBSTETRIQUE & FERTILITE | 2011年 / 39卷 / 02期
关键词
Breast cancer; Neoadjuvant chemotherapy; Anthracyclines; Predictive factors; Pathologic complete response (pCR); PATHOLOGICAL COMPLETE RESPONSE; GENE-EXPRESSION PROFILES; SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; TOPOISOMERASE-II; PROGNOSTIC-SIGNIFICANCE; INDUCTION CHEMOTHERAPY; HORMONAL RECEPTORS; DOXORUBICIN; MARKERS;
D O I
10.1016/j.gyobfe.2010.12.004
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives. - Anthracyclines chemotherapy remains primordial and impossible to circumvent in the treatment of breast cancer, in the adjuvant, metastatic and neoadjuvant setting. But some breast invasive tumors are resistant to anthracyclines. The neoadjuvant model is ideal to test the chemosensibility by selecting the well-responder patients and identifying the predictive factors of this response. Patients and methods. - We report a retrospective study of 126 patients treated at our institute during 2 years (January 2003-December 2004) for a breast cancer with primary chemotherapy. All the patients received anthracyclines according to protocol AC60 (doxorubicine plus cyclophosphamide). Results. - The clinical objective response rate (RO) was 67 % with a complete clinical response (RC) of 11 %. We found a pathological complete response (pCR) in seven patients (5,6 %) of the 126 cases. The statistical study identifies only two clinical factors as predictive of RC and pCR: tumoral size T2-T3 and clinical nodal status N0-N1, while the SBR grading and the hormonal receptors were not correlated. Discussion and conclusion. - Some clinical and histological factors are recognized as predictive for the benefit of anthracyclines neoadjuvant chemotherapy, and correlated to the pCR; we discuss our results through those of the literature, by exposing the current data. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:81 / 86
页数:6
相关论文
共 74 条
[1]   Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy [J].
Aas, T ;
Geisler, S ;
Eide, GE ;
Haugen, DF ;
Varhaug, JE ;
Bassoe, AM ;
Thorsen, T ;
Berntsen, H ;
Borresen-Dale, AL ;
Akslen, LA ;
Lonning, PE .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (04) :438-446
[2]  
Abrial C, 2006, B CANCER, V93, P663
[3]  
Aftimos G, 2000, J Med Liban, V48, P8
[4]  
Amat S, 2002, INT J ONCOL, V20, P791
[5]   Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].
Ayers, M ;
Symmans, WF ;
Stec, J ;
Damokosh, AI ;
Clark, E ;
Hess, K ;
Lecocke, M ;
Metivier, J ;
Booser, D ;
Ibrahim, N ;
Valero, V ;
Royce, M ;
Arun, B ;
Whitman, G ;
Ross, J ;
Sneige, N ;
Hortobagyi, GN ;
Pusztai, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293
[6]   Cancer incidence and mortality in France over the period 1980-2005 [J].
Belot, A. ;
Grosclaude, P. ;
Bossard, N. ;
Jougla, E. ;
Benhamou, E. ;
Delafosse, P. ;
Guizard, A. -V. ;
Molinie, F. ;
Danzon, A. ;
Bara, S. ;
Bouvier, A. -M. ;
Tretarre, B. ;
Binder-Foucard, F. ;
Colonna, M. ;
Daubisse, L. ;
Hedelin, G. ;
Launoy, G. ;
Le Stang, N. ;
Maynadie, M. ;
Monnereau, A. ;
Troussard, X. ;
Faivre, J. ;
Collignon, A. ;
Janoray, I. ;
Arveux, P. ;
Buemi, A. ;
Raverdy, N. ;
Schvartz, C. ;
Bovet, M. ;
Cherie-Challine, L. ;
Esteve, J. ;
Remontet, L. ;
Velten, M. .
REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2008, 56 (03) :159-175
[7]   Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy [J].
Bertheau, P ;
Plassa, F ;
Espié, M ;
Turpin, E ;
de Roquancourt, A ;
Marty, M ;
Lerebours, F ;
Beuzard, Y ;
Janin, A ;
de Thé, H .
LANCET, 2002, 360 (9336) :852-854
[8]   Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy [J].
Bertucci, F ;
Finetti, P ;
Rougemont, J ;
Charafe-Jauffret, E ;
Nasser, V ;
Loriod, W ;
Camerlo, J ;
Tagett, R ;
Tarpin, C ;
Houvenaeghel, G ;
Nguyen, C ;
Maraninchi, D ;
Jacquemier, J ;
Houlgatte, R ;
Birnbaum, D ;
Viens, P .
CANCER RESEARCH, 2004, 64 (23) :8558-8565
[9]   Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].
Bonadonna, G ;
Valagussa, P ;
Brambilla, C ;
Ferrari, L ;
Moliterni, A ;
Terenziani, M ;
Zambetti, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100
[10]   Global gene expression changes during neoadjuvant chemotherapy for human breast cancer [J].
Buchholz, TA ;
Stivers, DN ;
Stec, J ;
Ayers, M ;
Clark, E ;
Bolt, A ;
Sahin, AA ;
Symmans, WF ;
Hess, KR ;
Kuerer, HM ;
Valero, V ;
Hortobagyi, GN ;
Pusztai, L .
CANCER JOURNAL, 2002, 8 (06) :461-468